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Abstract We are witnessing the birth of a new variety of pharmacokinetics where non-integer-order
differential equations are employed to study the time course of drugs in the body: this is dubbed
“fractional pharmacokinetics”. The presence of fractional kinetics has important clinical implications
such as the lack of a half-life, observed, for example with the drug amiodarone and the associated
irregular accumulation patterns following constant and multiple-dose administration. Building models
that accurately reflect this behaviour is essential for the design of less toxic and more effective drug
administration protocols and devices. This article introduces the readers to the theory of fractional
pharmacokinetics and the research challenges that arise. After a short introduction to the concepts of
fractional calculus, and the main applications that have appeared in literature up to date, we address
two important aspects. First, numerical methods that allow us to simulate fractional order systems
accurately and second, optimal control methodologies that can be used to design dosing regimens to
individuals and populations.
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Introduction
Background
Diffusion is one of the main mechanisms of various transport processes in living species and plays
an important role in the distribution of drugs in the body. Processes such as membrane permeation,
dissolution of solids and dispersion in cellular matrices are considered to take place by diffusion.
Diffusion is typically described by Fick’s law, which, in terms of the pharmacokinetics of drugs, gives
rise to exponential washout curves that have a characteristic time scale, usually expressed as a half-life.
However, in the last few decades, strong experimental evidence has suggested that this is not always
true and diffusion processes that deviate from this law have been observed. These are either faster
(super-diffusion) or slower (sub-diffusion) modes of diffusion compared to the regular case [1, 2].
Such types of diffusion give rise to kinetics that are referred to as anomalous to indicate the fact
that they stray from the standard diffusion dynamics [1]. Moreover, anomalous kinetics can also re-
sult from reaction-limited processes and long-time trapping. Anomalous kinetics introduces memory
effects into the distribution process that need to be accounted for to correctly describe it. An distinc-
tive feature of anomalous power-law kinetics is that it lacks a characteristic time scale contrary to
exponential kinetics. A mathematical formulation that describes such anomalous kinetics is known as
fractal kinetics [3–5] where explicit power functions of time in the form of time-dependent coefficients
are used to account for the memory effects replacing the original rate constants. In pharmacokinet-
ics several datasets have been characterised by power laws, epmpirically [6, 7], while the first article
that utilised fractal kinetics in pharmacokinetics was [4]. Molecules that their kinetics presents power
law behaviour incude those distributed in deeper tissues, such as amiodarone [8] and bone-seeking
elements, such as calcium, lead, strontium and plutonium [4, 9].
An alternative theory to describe anomalous kinetics employs fractional calculus [10, 11], which
introduces derivatives and integrals of fractional order, such as half or three quarters. Although frac-
tional calculus was introduced by Leibniz more than 300 years ago, it is only within the last couple
of decades that real-life applications have been explored [12–14]. It has been shown that differen-
tial equations with fractional derivatives (FDEs) describe experimental data of anomalous diffusion
more accurately. Although fractional-order derivatives were first introduced as a novel mathematical
concept with unclear physical meaning, nowadays, a clear connection between diffusion over fractal
spaces (such as networks of capillaries) and fractional-order dynamics has been established [15–18]. In
particular, in anomalous diffusion the standard assumption that the mean square displacement 〈x2〉
is proportional to time does not hold. Instead, it is 〈x2〉 ∼ t2/d, where d 6= 2 is the associated fractal
dimension [19–21].
Fractional kinetics [22] was introduced in the pharmaceutical literature in [23] and the first example
of fractional pharmacokinetics which appeared in that article was amiodarone, a drug known for its
power-law kinetics [7]. Since then, other applications of fractional pharmacokinetics have appeared in
the literature. Kytariolos et al. [24] presented an application of fractional kinetics for the development
of nonlinear in vitro-in vivo correlations. Popovic´ et al. have presented several applications of fractional
pharmacokinetics to model drugs, namely for diclofenac [25], valproic acid [26], bumetanide [27] and
methotrexate [28]. Copot et al. have further used a fractional pharmacokinetics model for propofol [29].
In most of these cases the fractional model has been compared with an equivalent ordinary PK
model and was found superior. FDEs have been proposed to describe drug response too, apart from
their kinetics. Verotta has proposed several alternative fractional PKPD models that are capable of
describing pharmacodynamic times series with favourable properties [30]. Although these models are
empirical, i.e., they have no mechanistic basis, they are attractive since the memory effects of FDEs
can link smoothly the concentration to the response with a variable degree of influence, while the
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shape of the responses generated by fractional PKPD models can be very flexible and parsimonious
(modelled using few parameters).
Applications of FDEs in pharmacokinetics fall in the scope of the newly-coined discipline of math-
ematical pharmacology [31] to which this issue is dedicated. Mathematical pharmacology utilises ap-
plied mathematics, beyond the standard tools used commonly in pharmacometrics, to describe drug
processes in the body and assist in controlling them.
This paper introduces the basic principles of fractional calculus and FDEs, reviews recent appli-
cations of fractional calculus in pharmacokinetics and discusses their clinical implications. Moreover,
some aspects of drug dosage regimen optimisation based on control theory are presented for the case
of pharmacokinetic models that follow fractional kinetics. Indeed, in clinical pharmacokinetics and
therapeutic drug monitoring, dose optimisation is carried out usually by utilising Bayesian methodol-
ogy. Optimal control theory is a powerful approach that can be used to optimise drug administration,
which can handle complicated constraints and has not been used extensively for this task. The case of
fractional pharmacokinetic models is of particular interest for control theory and poses new challenges.
A problem that has hindered the applications of fractional calculus is the lack of efficient general-
purpose numerical solvers, as opposed to ordinary differential equations. However, in the past few
years significant progress has been achieved in this area. This important issue is discussed in the
paper and some techniques for numerical solution of FDEs are presented.
Fractional derivatives
Derivatives of integer order n ∈ N, of functions f : R → R are well defined and their properties have
been extensively studied in real analysis. The basis for the extension of such derivatives to real orders
α ∈ R commences with the definition of an integral of order α which hinges on Cauchy’s iterated
(n-th order) integral formula and gives rise to the celebrated Riemann-Liouville integral rl0 I
α
t [32]:
rl
0 I
α
t f(t) = 0D
−α
t f(t) =
1
Γ (α)
∫ t
0
(t− τ)α−1f(τ)dτ, (1)
where Γ is the Euler gamma function. In Eq. (1) we assume that f is such that the involved integral
is well-defined and finite. This is the case if f is continuous everywhere except at finitely many points
and left-bounded, i.e., {f(x); 0 ≤ x ≤ t} is bounded for every t ≥ 0. Note that for α ∈ N, rl0 Iαt f is
equivalent to the ordinary α-th order integral. Hereafter, we focus on derivatives of order α ∈ [0, 1] as
only these are of interest to date in the study of fractional pharmacokinetics.
The left-side subscript 0 of the 0D
α
t and
rl
0 I
α
t operators, denotes the lower end of the integration
limits, which in this case has been assumed to be zero. However, alternative lower bounds can be
considered leading to different definitions of the fractional derivative with slightly different properties.
When the lower bound is −∞, the entire history of the studied function is accounted for, which is
considered preferable in some applications and is referred to as the Weyl definition [12].
It is intuitive to define a fractional-order derivative of order α via 0D
α
t = D
1
0D
α−1
t = D
1 rl
0 I
α−1
,
(where D1 is the ordinary derivative of order 1), or equivalently
0D
α
t f(t) =
d
dt
[
1
Γ (1−α)
∫ t
0
f(τ)
(t− τ)α dτ
]
(2)
This is the Riemann-Liouville definition — one of the most popular constructs in fractional calculus.
One may observe that the fractional integration is basically a convolution between function f and a
power law of time, i.e., 0D
−α
t f(t) = t
α−1 ∗ f(t), where ∗ denotes the convolution of two functions.
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This explicitly demonstrates the memory effects of the studied process. Fractional derivatives possess
properties that are not straightforward or intuitive; for example, the half derivative of a constant
f(t) = λ with respect to t does not vanish and instead is 0D
1/2
t λ = λ/
√
pit.
Perhaps the most notable shortcoming of the Riemann-Liouville definition with the 0 lower bound
is that when used in differential equations it gives rise to initial conditions that involve the fractional
integral of the function and are difficult to interpret physically. This is one of the reasons the Weyl
definition was introduced, but this definition may not be very practical for most applications either,
as it involves an initial condition at time −∞ [12, 33].
A third definition of the fractional derivative, which is referred to as the Caputo definition is
preferable for most physical processes as it involves explicitly the initial condition at time zero. The
definition is:
c
0D
α
t f(t) =
1
Γ (1−α)
∫ t
0
df(τ)
dτ
(t− τ)α dτ (3)
where the upper-left superscript c stands for Caputo. The Caputo derivative is interpreted as c0D
α
t =
rl
0 I
α−1
D1, that is D1 and rl0 I
α−1
are composed in the opposite way compared to the Riemann-Liouville
definition. The Caputo derivative gives rise to initial value problems of the form
c
0D
α
t x(t) = F (x(t)), (4a)
x(0) = x0. (4b)
This definition for the fractional derivative, apart from the more familiar initial conditions, comes
with some properties similar to those of integer-order derivatives, one of them being that the Caputo
derivative of a constant is in fact zero. Well-posedeness conditions, for the existence and uniqueness
of solutions, for such fractional-order initial value problems are akin to those of integer-order prob-
lems [34],[11, Chap. 3]. The various definitions of the fractional derivative give different results, but
these are not contradictory since they apply for different conditions and it is a matter of choosing the
appropriate one for each specific application. All definitions collapse to the usual derivative for integer
values of the order of differentiation.
A fourth fractional derivative definition, which is of particular interest is the Gru¨nwald-Letnikov,
which allows the approximate discretisation of fractional differential equations. The Gru¨nwald-Letnikov
derivative, similar to integer order derivatives, is defined via a limit of a fractional-order difference. Let
us first define the Gru¨nwald-Letnikov difference of order α and step-size h of a left-bounded function
f as
gl∆
α
hf(t) =
1
hα
bt/hc∑
j=0
cαj f(t− jh), (5)
with cα0 = 1 and for j ∈ N>0
cαj = (−1)j
j−1∏
i=0
α− i
i+ 1
. (6)
The Gru¨nwald-Letnikov difference operator leads to the definition of the Gru¨nwald-Letnikov deriva-
tive of order α which is defined as [33, Section 20]
glD
α
t f(t) = lim
h→0+
gl∆
α
hf(t), (7)
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insofar as the limit exists. This definition is of great importance in practice, as it allows us to replace
glDt with
gl∆
α
h provided that h is adequately small, therefore it serves as an Euler-type discretisation
of fractional-order continuous time dynamics. By doing so, we produce a discrete-time yet infinite-
dimensional approximation of the system since gl∆
α
hf(t) depends on f(t−jh) for all j ∈ N>0. However,
we may truncate this series up to a finite history ν, defining
gl∆
α
h,νf(t) =
1
hα
min{ν,bt/hc}∑
j=0
cαj f(t− jh). (8)
This leads to discrete-time finite-memory approximations which are particularly useful as we shall
discuss in what follows.
Fractional Kinetics
The most common type of kinetics encountered in pharmaceutical literature are the so called “zero
order” and “first order”. Here the “order” refers to the order of linearity and is not to be confused
with the order of differentiation, i.e., a zero order process refers to a constant rate and a first order
to a proportional rate. The fractional versions of these types of kinetics are presented below and take
the form of fractional-order ordinary differential equations. Throughout this presentation the Caputo
version of the fractional derivative is considered for reasons already explained.
Zero-order kinetics
The simplest kinetic model is the zero-order model where it is assumed that the rate of change of the
quantity q, expressed in [mass] units, is constant and equal to k0, expressed in [mass]/[time] units.
Zero-order systems are governed by differential equations of the form
dq
dt
= k0. (9)
The solution of this equation with initial condition q(0) = 0 is
q(t) = k0t. (10)
The fractional-order counterpart of such zero-order kinetics can be obtained by replacing the
derivative of order 1 by a derivative of fractional order α, that is
c
0D
α
t q(t) = k0,f , (11)
where k0,f is a constant with units [mass]/[time]
α. The solution of this equation for initial condition
q(0) = 0 is a power law for t > 0 [11]
q(t) =
k0,f
Γ (α+ 1)
tα. (12)
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First-order kinetics
The first-order differential equation, where the rate of change of the quantity q is proportional to its
current value, is described by the ordinary differential equation
dq
dt
= −k1q(t). (13)
Its solution with initial condition of q(0) = q0 is given by the classical equation of exponential decay
q(t) = q0 exp(−k1t). (14)
Likewise, the fractional-order analogue of such first-order kinetics is derived by replacing d/dt by
the fractional-order derivative c0D
α
t yielding the following fractional differential equation
c
0D
α
t q(t) = −k1,fq(t), (15)
where k1,f is a constant with [time]
−α units. The solution of this equation can be found in most books
or papers of the fast growing literature on fractional calculus [11] and for initial condition q(0) = q0
it is
q(t) = q0Eα(−k1,f tα), (16)
where Eα is the Mittag-Leffler function [11] which is defined as
Eα(t) =
∞∑
k=0
tk
Γ (αk + 1)
. (17)
The function Eα(t) is a generalisation of the exponential function and it collapses to the exponential
when α = 1, i.e., E1(t) = exp(t). Alternatively, Eq. (16) can be reparametrised by introducing a time
scale parameter with regular time units, τf = k
−1/α
1,f and then becomes q(t) = q0Eα(−(t/τf )α). The
solution of Eq. (15) basically means that the fractional derivative of order α of the function Eα(tα)
is itself a function of the same form, exactly like the classic derivative of an exponential is also an
exponential.
It also makes sense to restrict α to values 0 ≤ α ≤ 1, since for values of a larger than 1 the solution
of Eq. (15) is not monotonic and negative values for q may appear, therefore, it is not applicable in
pharmacokinetics and pharmacodynamics. Based on these elementary equations the basic relations
for the time evolution in drug disposition can be formulated, with the assumption of diffusion of drug
molecules taking place in heterogeneous space. The simplest fractional pharmacokinetic model is the
one-compartment model with i.v. bolus administration and the concentration, c, can be expressed by
Eq. (16) divided by a volume of distribution, as
c(t) = c0Eα(−k1,f tα), (18)
with α ≤ 1 and c0 is the ratio [dose]/[apparent volume of distribution]. This equation for times t 1
behaves as a stretched exponential, i.e., as ∼ exp(−k1,f tα/Γ (1 + α)), while for large values of time
it behaves as a power-law, ∼t−α/Γ (1 − α) (see Figure 1) [35]. This kinetics is, therefore, a good
candidate to describe various datasets exhibiting power-law-like kinetics due to the slow diffusion of
the drug in deeper tissues. Moreover, the relevance of the stretched exponential (Weibull) function
with the Mittag-Leffler function probably explains the successful application of the former function in
describing drug release in heterogeneous media [36]. Eq. (18) is a relationship for the simplest case of
fractional pharmacokinetics. It accounts for the anomalous diffusion process, which may be considered
to be the limiting step of the entire kinetics. Classic clearance may be considered not to be the limiting
process here and is absent from the equation.
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Fig. 1 Amount-time profile according to Eq. (16) for α = 0.5 (solid curve) along with its approximation at values of
t close to 0 by a stretched exponential function exp(−t1/2/Γ (1.5)) (bottom dashed curve) and an approximation at
high values of t by a power function t−1/2/Γ (0.5) (top dashed-dotted curve). Note that the time axis is logarithmic.
The evolution of the amount of drug starts as a stretched exponential and eventually shapes as a power function.
The Laplace transform for FDEs
Fractional differential equations (FDEs) can be easily written in the Laplace domain since each of the
fractional derivatives can be transformed similarly to the ordinary derivatives, as follows, for order
α ≤ 1:
L{c0Dαt f(t)} = sαF (s)− sα−1f(0+), (19)
where F (s) is the Laplace transform of f(t) [11]. For α = 1, Eq. (19) reduces to the classic well-known
expression for ordinary derivatives, that is, L{f˙(t)} = sF (s)− f(0+).
Let us take as an example the following simple FDE
c
0D
1/2
t q(t) = −q(t), (20)
with initial value q(0) = 1 which can be written in the Laplace domain, by virtue of Eq. (19), as
follows
s
1/2Q(s)− s−1/2q(0) = −Q(s), (21)
where Q(s) = L{q(t)}(s) is the Laplace transform of q. After simple algebraic manipulations, we
obtain
Q(s) =
1
s+
√
s
. (22)
By applying the inverse Laplace transform to Eq. (22) the closed-form analytical solution of this FDE
can be obtained; this involves a Mittag-Leffler function of order one half. In particular,
q(t) = E1/2(−t1/2) = et(1 + erf(−
√
t)). (23)
Although more often than not it is easy to transform an FDE in the Laplace domain, it is more
difficult to apply the inverse Laplace transform so as to solve it explicitly for the system variables so
that an analytical solution in the time domain is obtained. However, it is possible to perform that step
numerically using a numerical inverse Laplace transform (NILT) algorithm [37] as described above.
8 Pantelis Sopasakis et al.
Fractional Pharmacokinetics
Multi-compartmental models
A one-compartment pharmacokinetic model with i.v. bolus administration can be easily fractionalised
as in Eq. (15) by changing the derivative on the left-hand-side of the single ODE to a fractional order.
However, in pharmacokinetics and other fields where compartmental models are used, two or more
ODEs are often necessary and it is not as straightforward to fractionalise systems of differential
equations, especially when certain properties such as mass balance need to be preserved.
When a compartmental model with two or more compartments is built, typically an outgoing mass
flux becomes an incoming flux to the next compartment. Thus, an outgoing mass flux that is defined
as a rate of fractional order, cannot appear as an incoming flux into another compartment, with a
different fractional order, without violating mass balance [38]. It is therefore, in general, impossible
to fractionalise multi-compartmental systems simply by changing the order of the derivatives on the
left hand side of the ODEs.
One approach to the fractionalisation of multi-compartment models is to consider a common
fractional order that defined the mass transfer from a compartment i to a compartment j: the outflow
of one compartment becomes an inflow to the other. This implies a common fractional order known as
a commensurate order. In the general case, of non-commensurate-order systems, a different approach
for fractionalising systems of ODEs needs to be applied.
In what follows, a general form of a fractional two-compartment system is considered and then
generalised to a system of an arbitrary number of compartments, which first appeared in [39]. A
general ordinary linear two-compartment model, is defined by the following system of linear ODEs,
dq1(t)
dt
= −k12q1(t) + k21q2(t)− k10q1(t) + u1(t), (24a)
dq2(t)
dt
= k12q1(t)− k21q2(t)− k20q2(t) + u2(t), (24b)
where q1(t) and q2(t) are the mass or molar amounts of material in the respective compartments and
the kij constants control the mass transfer between the two compartments and elimination from each
of them. The notation convention used for the indices of the rate constants is that the first corresponds
to the source compartment and the second to the target one, e.g. k12 corresponds to the transfer from
compartment 1 to 2, k10 corresponds to the elimination from compartment 1, etc. The units of all
the kij rate constants are (1/[time]). ui(t) are input rates in each compartment which may be zero,
constant or time dependent. Initial values for q1 and q2 have to be considered also, q1(0) and q2(0),
respectively.
In order to fractionalise this system, first the ordinary system is integrated, obtaining a system
of integral equations and then the integrals are fractionalised as shown in [39]. Finally, the fractional
integral equations, are differentiated in an ordinary way. The resulting fractional system contains
ordinary derivatives on the left hand side and fractional Riemann-Liouville derivatives on the right
hand side:
dq1(t)
dt
= −k12,f 0D1−α12t q1(t) + k21,f 0D1−α21t q2(t)− k10,f 0D1−α10t q1(t) + u1(t), (25a)
dq2(t)
dt
= k12,f 0D
1−α12
t q1(t)− k21,f 0D1−α21t q2(t)− k20,f 0D1−α20t q2(t) + u2(t), (25b)
where 0 < αij ≤ 1 is a constant representing the order of the specific process. Different values for the
orders of different processes may be considered, but the order of the corresponding terms of a specific
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process are kept the same when these appear in different equations, e.g., there can be an order α12 for
the transfer from compartment 1 to 2 and a different order α21 for the transfer from compartment 2
to 1, but the order for the corresponding terms of the transfer, from compartment 1 to 2, α12, is the
same in both equations. Also the index f in the rate constant was added to emphasise the fact that
these are different to the ones of Eq. (24) and carry units [time]−α.
It is convenient to rewrite the above system Eq. (25) with Caputo derivatives. An FDE with
Caputo derivatives accepts the usual type of initial conditions involving the variable itself, as opposed
to RL derivatives which involve an initial condition on the derivative of the variable, which is not
practical. When the initial value of q1 or q2 is zero then the respective RL and Caputo derivatives
are the same. This is convenient since a zero initial value is very common in compartmental analysis.
When the initial value is not zero, converting to a Caputo derivative is possible, for the particular
term with a non-zero initial value. The conversion from a RL to a Caputo derivative of the form that
appears in Eq. (25) is done with the following expression:
0D
1−αij
t qi(t) =
c
0D
1−αij
t qi(t) +
qi(0)t
αij−1
Γ (αij)
. (26)
Summarising the above remarks about initial conditions, we may identify three cases: (i) The initial
condition is zero and then the derivative becomes a Caputo by definition. (ii) The initial condition is
non-zero, but it is involved in a term with an ordinary derivative so it is treated as usual. (iii) The
initial condition is non-zero and is involved in a fractional derivative which means that in order to
present a Caputo derivative, an additional term, involving the initial value appears, by substituting
Eq. (26). Alternatively, a zero initial value for that variable can be assumed, with a Dirac delta
input to account for the initial quantity for that variable. So, a general fractional model with two
compartments, Eq. (25), was formulated, where the fractional derivatives can always be written as
Caputo derivatives. It is easy to generalise the above approach to a system with an arbitrary number
of n compartments as follows
dqi(t)
dt
= −ki0 c0D1−αi0t qi(t)−
∑
j 6=i
kij
c
0D
1−αij
t qi(t) +
∑
j 6=i
kji
c
0D
1−αji
t qj(t) + ui(t), (27)
for i = 1, . . . , n, where Caputo derivatives have been considered throughout since, as explained above,
this is feasible. This system of Eqs. (27) is too general for most purposes as it allows every compartment
to be connected with every other. Typically the connection matrix would be much sparser than
that, with most compartments being connected to just one neighbouring compartment while only a
few “hub” compartments would have more than one connections. The advantage of the described
approach of fractionalisation is that each transport process is fractionalised separately, rather than
fractionalising each compartment or each equation. Thus, processes of different fractional orders can
co-exist since they have consistent orders when the corresponding terms appear in different equations.
Also, it is important to note that dynamical systems of the type (27) do not suffer from pathologies
such as violation of mass balance or inconsistencies with the units of the rate constants.
As mentioned, FDEs can be easily written in the Laplace domain. In the case of FDEs of the form
of Eq. (27), where the fractional orders are 1 − αij , the Laplace transform of the Caputo derivative
becomes
L{c0D1−αijt qi(t)} = s1−αijQi(s)− s−αijqi(0). (28)
An alternative approach for fractionalisation of non-commensurate fractional pharmacokinetic systems
has been proposed in [40], where the conditions that the pharmacokinetic parameters need to satisfy
for the mass balance to be preserved have been defined.
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A one-compartment model with constant rate input
After the simplest fractional pharmacokinetic model with one-compartment and i.v. bolus of Eq. (18),
the same model with fractional elimination, but with a constant rate input is considered [39]. Even
in this simple one-compartment model, it is necessary to employ the approach of fractionalising each
process separately, described above, since the constant rate of infusion is not of fractional order. That
would have been difficult if one followed the approach of changing the order of the derivative of the
left hand side of the ODE, however here it is straightforward. The system can be described by the
following equation
dq(t)
dt
= k01 − k10,f c0D1−αt q(t), (29)
with q(0) = 0 and where k01 is a zero-order input rate constant, with units [mass]/[time], k10,f is a
rate constant with units [time]−α and α is a fractional order less than 1. Eq. (29) can be written in
the Laplace domain as
sQ(s)− q(0) = k01
s
− k10,f (s1−αQ(s)− s−αq(0)). (30)
Since q(0) = 0, Eq. (30) can be solved to obtain
Q(s) =
k01s
α−2
sα + k10,f
. (31)
By applying the following inverse Laplace transform formula (Equation (1.80) in [11], page 21):
L−1
{
sµ−ν
sµ + k
}
= tν−1Eµ,ν(−ktµ), (32)
where Eµ,ν is the Mittag-Leffler function with two parameters. For µ = α and ν = 2, we obtain
q(t) = k01tEα,2(−k10,f tα). (33)
In Theorem 1.4 of [11], the following expansion for the Mittag-Leffler function is proven to hold
asymptotically as |z| → ∞:
Eµ,ν(z) = −
p∑
k=1
z−k
Γ (ν − µ) +O(|z|
1−p). (34)
Applying this formula for Eq. (33) and keeping only the first term of the sum since the rest are of
higher order, the limit of Eq. (33) for t going to infinity can be shown that it is limt→∞ q(t) =∞ for
all 0 < α < 1 [39].
The fact that the limit of q(t) in Eq. (33) diverges as t goes to infinity, for α < 1, means that
unlike the classic case, for α = 1 — where (33) approaches exponentially the steady state k01/k10,f , for
α < 1 — there is infinite accumulation. In Figure 2 a plot of (33) is shown for α = 0.5 demonstrating
that in the fractional case the amount grows unbounded. In the inset of Figure 2 the same profiles
are shown a 100-fold larger time span, demonstrating the effect of continuous accumulation.
The lack of a steady state under constant rate administration which results to infinite accumulation
is one of the most important clinical implications of fractional pharmacokinetics. It is clear that this
implication extents to repeated doses as well as constant infusion, which is the most common dosing
regimen, and can be important in chronic treatments. In order to avoid accumulation, the constant
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Fig. 2 Amount-time profiles for α = 0.5: (solid line) amount of drug versus time according to Eq. (33) with constant
infusion where there is unbounded accumulation of drug, (dashed line) time-profile according to Eq. (35), with power-
law infusion where the amount of drug approaches a steady state. (Inset) The same profiles for 100 times longer time
span.
rate administration must be adjusted to a rate which decreases with time. Indeed, in Eq. (29), if the
constant rate of infusion k01 is replaced by the term f(t) = k01t
1−α, [32] the solution of the resulting
FDE is, instead of Eq. (33), the following
q(t) = k01Γ (α)t
αEα,α+1(−k10,f tα). (35)
The drug quantity q(t) in Eq. (35) converges to the steady state Γ (α)k01/k10,f as time goes to
infinity, while for the special case of α = 1, the steady state is the usual k01/k10,f . Similarly, for the
case of repeated doses, if a steady state is intended to be achieved, in the presence of fractional
elimination of order α, then the usual constant rate of administration, e.g., a constant daily dose,
needs to be replaced by an appropriately decreasing rate of administration. As shown in [32], this
can be either the same dose, but given at increasing inter-dose intervals, i.e., Ti = (T
α
i−1 + α∆τ
α)
1/α,
where Ti is the time of the i-th dose and ∆τ is the inter-dose interval of the corresponding kinetics
of order α = 1; or a decreasing dose given at constant intervals, i.e., q0,i = q0/α((i + 1)
α − iα). In
this way, an ever decreasing administration rate is implemented which compensates the decreasing
elimination rate due to the fractional kinetics.
A two-compartment i.v. model
Based on the generalised approach for the fractionalisation of compartmental models, which allows
mixing different fractional orders, developed above, a two-compartment fractional pharmacokinetic
model is considered, shown schematically in Figure 3. Compartment 1 (central) represents general
circulation and well perfused tissues while compartment 2 (peripheral) represents deeper tissues.
Three transfer processes (fluxes) are considered: elimination from the central compartment and a
mass flux from the central to the peripheral compartment, which are both assumed to follow classic
kinetics (order 1), while a flux from the peripheral to the central compartment is assumed to follow
slower fractional kinetics accounting for tissue trapping [23, 41].
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Fig. 3 A fractional two-compartment PK model with an i.v. bolus. Elimination from the central compartment
and a mass flux from the central to the peripheral compartment, which are both assumed to follow classic kinetics
(order 1), while a flux from the peripheral to the central compartment is assumed to follow slower fractional kinetics,
accounting for tissue trapping (dashed arrow).
The system is formulated mathematically as follows:
dq1(t)
dt
= −(k12 + k10)q1(t) + k21,f c0D1−αt q2(t), (36a)
dq2(t)
dt
= k12q1(t)− k21,f c0D1−αt q2(t), (36b)
where α < 1 and initial conditions are q1(0) = q1,0, q2(0) = 0 which account for a bolus dose injection
and no initial amount in the peripheral compartment. Note, that it is allowed to use Caputo derivatives
here since the fractional derivatives involve only terms with q2 for which there is no initial amount,
which means that Caputo and RL derivatives are identical.
Applying the Laplace transform, to the above system the following algebraic equations are ob-
tained:
sQ1(s)− q1(0) = −(k12 + k10)Q1(s) + k21(s1−αQ2(s)− s−αq2(0)), (37a)
sQ2(s)− q2(0) = k12Q1(s)− k21,f (s1−αQ2(s)− s−αq2(0)). (37b)
Solving for Q1(s) and Q2(s) and substituting the initial conditions,
Q1(s) =
q1,0(s
α + k21,f )
(s+ k12 + k10)(sα + k21,f )− k12k21,f (38a)
Q2(s) =
q1,0s
α−1k12
(s+ k12 + k10)(sα + k21,f )− k12k21,f (38b)
Using the above expression for Q1 and Q2, Eq. (38a) and Eq. (38b), respectively, can be used to
simulate values of q1(t) and q2(t) in the time domain by an NILT method. Note, that primarily, q1(t)
is of interest, since in practice we only have data from this compartment. The output for q1(t) from
this numerical solution may be combined with the following equation
c(t) =
q1(t)
V
, (39)
where c is the drug concentration in the blood and V is the apparent volume of distribution. Eq. (39)
can be fitted to pharmacokinetic data in order to estimate parameters V , k10, k12, k21,f and α.
The closed-form analytical solution of Eq. (36), can be expressed in terms of an infinite series of
generalised Wright functions as demonstrated in the book by Kilbas et al. [42], but these solutions
Fractional Calculus in Pharmacokinetics 13
are hard to implement and apply in practice. Moloni in [43] derived analytically the inverse Laplace
transform of Q1(s) as:
q1(t) = q1,0
∞∑
n=0
(−1)nkn21,f
n∑
l=0
kl10n!
(n− l)!l!
(
tl+αnEn+11,l+αn+1(−(k10 + k12)t)
+ tl+α(n+1)En+11,l+α(n+1)+1(−(k10 + k12)t)
)
, (40a)
while for Q2 the inverse Laplace transform works out to be [43]:
q2(t) = q1,0k12
∞∑
n=0
(−1)nkn21,f
n∑
l=0
kl10n!
(n− l)!l! t
l+αnEn+11,l+αn+2(−(k10 + k12)t). (40b)
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Fig. 4 Concentration-time profile of amiodarone in the central compartment. The solid line corresponds to the
fractional-order pharmacokinetic model of Eq. (36) with the parameter estimates: α = 0.587, k10 = 1.49 days
−1,
k12 = 2.95 days
−1, k21,f = 0.48 days−α and q0/V = 4.72 ng/ml. The circles correspond to experimental measurements.
An application of the fractional two compartment model, the system of Eq. (36) to amiodarone
PK data was presented in [39]. Amidarone is an antiarrhythmic drug known for its anomalous, non-
exponential pharmacokinetics, which has important clinical implications due to the accumulation
pattern of the drug in long-term administration. The fractional two-compartment model of the previ-
ous section was used to analyse an amiodarone i.v. data-set which first appeared in [44] and estimates
of the model parameters were obtained. Analysis was carried out in MATLAB while the values for
q1(t) of Eq. (40a) were simulated using a NILT algorithm [37] from the expression of Q1(s) in the
Laplace domain. In Figure 4 the model-based predictions are plotted together the data demonstrating
good agreement for the 60 day period of this study. The estimated fractional order was α = 0.587 and
the non-exponential character of the curve is evident, while the model follows well the data both for
long and for short times, unlike empirical power-laws which explode at t = 0.
Numerical methods for fractional-order systems
For simple fractional-order models, as we discussed previously, there may exist closed-form analytical
solutions which involve the one-parameter or two-parameters Mittage-Leffler function, or are given by
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more intricate analytical expressions such as Eq. (40). Interestingly, even for simple analytical solutions
such as Eq. (16), the Mittag-Leffler function itself is evaluated by solving an FDE numerically [45].
This fact, without discrediting the value of analytical solutions, necessitates the availability of reliable
numerical methods that allow us to simulate and study fractional-order systems. The availability of
accurate discrete-time approximations of the trajectories of such systems is important not only for
simulating, but also for the design of open-loop or closed-loop administration strategies, based on
control theory [46]. Time-domain approximations are less parsimonious than s-domain ones, but are
more suitable for control applications as we discuss in the next section.
There can be identified four types of solutions for fractional-order differential equations: (i) closed-
form analytical solutions, (ii) approximations in the Laplace s-domain using integer-order rational
transfer functions, (iii) numerical approximation schemes in the discrete time domain and (iv) numer-
ical inverse Laplace transforms. Each of these comes with certain advantages as well as limitations; for
example, closed-form analytical solutions are often not available, while the inverse Laplace function
requires an explicit closed form for ui(t) so it cannot be used for administration rates that are defined
implicitly or are arbitrary signals. Approximations in the s-domain are powerful modelling tools, but
they fail to provide error bounds on the concentration of the administered drug in the time domain
which are necessary in clinical practice.
In regard to closed-form analytical solutions, when available, they involve special functions such
as the Mittag-Leffler function Eα,β(t) =
∑∞
k=0 t
k/Γ (αk + β) whose evaluation calls, in turn, for some
numerical approximation scheme. Analytical closed-form solutions of fractional differential equations
are available for pharmacokinetic systems [47]. Typically for the evaluation of this function we resort
to solving an FDE numerically [48–50] because the series in the definition of Eα,β(t) converges rather
slowly and no exact error bounds as available so as to establish meaningful termination criteria.
Transfer functions and integer-order approximations
Fractional-order systems, like their integer-order counterparts, can be modelled in the Laplace s-
domain via transfer functions, that is,
Fij(s) =
Qj(s)
Ui(s)
, (41)
where Qj(s) and Ui(s) are the Laplace transforms of the drug quantity qj(t) and the administration
rate ui(t). If the pharmacokinetics is described by linear fractional-order models such as the ones
discussed above, Fij will be a fractional-order rational function (a quotient of polynomials with real
exponents).
Rational approximations aim at approximating such transfer functions — which involve terms of
the form sα, α ∈ R — by ordinary transfer functions of the form
F˜ij(s) =
Pij(s)
Sij(s)
, (42)
where Pij and Sij are polynomials and the degree of Pij is no larger than the degree of Sij . For
convenience with notation, we henceforth drop the subscripts ij.
Pade´ Approximation: The Pade´ approximation of order [m/n], m,n ∈ N, at a point s0 is rather
popular and leads to rational functions with degP = m and degS = n [51].
Matsuda-Fujii continuous fractions approximation: This method consists in interpolating a func-
tion F (s), which is treated as a black box, across a set of logarithmically spaced points [52]. By letting
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the selected points be sk, k = 0, 1, 2, . . . , the approximation is written as the continued fractions
expansion
F (s) = α0 +
s− s0
α1 +
s−s1
α2+
s−s2
α3+...
(43)
where, αi = υi(si), υ0(s) = H(s) and υi+1(s) =
s−si
υi(s)−αi .
Oustaloup’s method: Oustaloup’s method is based on the approximation of a function of the form:
H(s) = sα, (44)
with α > 0 by a rational function
Ĥ(s) = c0
N∏
k=−N
s+ ωk
s+ ω′k
, (45)
within a range of frequencies from ωb to ωh [53]. The Oustaloup method offers an approximation at
frequencies which are geometrically distributed about the characteristic frequency ωu =
√
ωbωh — the
geometric mean of ωb and ωh. The parameters ωk and ω
′
k are determined via the design formulas [54]
ω′k = ωb
(
ωh
ωb
) k+N+0.5(1+α)
2N+1
, (46a)
ωk = ωb
(
ωh
ωb
) k+N+0.5(1−α)
2N+1
, (46b)
c0 =
(
ωh
ωb
)− r
2
N∏
k=−N
ωk
ω′k
. (46c)
Parameters ωb, ωh and N are design parameters of the Oustaloup method.
There are a few more methods which have been proposed in the literature to approximate fractional-
order systems by rational transfer functions such as [55, 56], as well as data-driven system identification
techniques [57].
Time domain approximations
Several methods have been proposed which attempt to approximate the solution to a fractional-order
initial value problem in the time domain.
Gru¨nwald-Letnikov: This is the method of choice in the discrete time domain where glD
α
t x(t) is
approximated by its discrete-time finite-history variant (gl∆
α
h,νx)k which is proven to have bounded
error with respect to (gl∆
α
hx)k [58]. The boundedness of this approximation error is a singular char-
acteristic of this approximation method and is suitable for applications in drug administration where
it is necessary to guarantee that the drug concentration in the body will remain within certain lim-
its [58]. As an example, system (15) is approximated (with sampling time h) by the discrete-time
linear system
1
hα
min{ν,bt/hc}∑
j=0
cαj qk+1−j = −k1,fqk, (47)
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where qk = q(kh).
The discretisation of the Gru¨nwald-Letnikov derivative suffers from the fact that the required
memory grows unbounded with the simulation time. The truncation of the Gru¨nwald-Letnikov series
up to some finite memory gives rise to viable solution alorithms which can be elegantly described
using triangular strip matrices as described in [59] and are available as a MATLAB toolbox.
Approximation by parametrisation: Approximate time-domain solutions can be obtained by as-
suming a particular parametric form for the solution. Such a method was proposed by Hennion and
Hanert [32] where q(t) is approximated by finite-length expansions of the form
∑N
j=0Ajφj(t), where
φj are Chebyshev polynomials and Aj are constant coefficients. By virtue of the computability of
fractional derivatives of φj , the parametric approximation is plugged into the fractional differential
equation which, along with the initial conditions, yields a linear system. What is notable in this
method is that expansions as short as N = 10 lead to very low approximation errors. Likewise, other
parametric forms can be used. For example, [60] used a Fourier-type expansion and [61] used piecewise
quadratic functions.
Numerical integration methods: Fractional-order initial value problems can be solved with various
numerical methods such as the Adams-Bashforth-Moulton predictor-corrector (ABMPC) method [62]
and fractional linear multi-step methods (FLMMs) [63, 64]. These methods are only suitable for
systems of FDEs in the form
c
0D
γ
t x(t) = f(t, x(t)), (48a)
x(k)(0) = x0,k, k = 0, . . . ,m− 1 (48b)
where γ is a rational, and m = dγe. Typically in pharmacokinetics we encounter cases with 0 < γ ≤ 1,
therefore, we will have m = 1.
Let us give an example on how this applies to the two-compartment model we presented above. In
order to bring Eq. (36) in the above form, we need to find a rational approximation of two derivatives,
1 − α and 1. If we can find a satisfying rational approximation of 1 − a u p/q, then the first order
derivative follows trivially. Now, Eq. (36) can be written as
c
0D
γ
t x0 = x1 (49a)
c
0D
γ
t x1 = x2 (49b)
...
c
0D
γ
t xq−1 = −(k12 + k10)x0+k21,fxq+p+u (49c)
c
0D
γ
t xq = xq+1 (49d)
...
c
0D
γ
t x2q−1 = k12x0 − k21,fxq+p (49e)
with initial conditions x0(0) = q1(0), xq(0) = q2(0) and xi(0) = 0 for i /∈ {1, q}, and γ = 1/q.
This system is in fact a linear fractional-order system for which closed-form analytical solutions are
available [45, Thm. 2.5]. In particular, Eq. (49) can be written concisely in the form
c
0D
γ
t x(t) = Ax(t) +Bu(t) (50a)
x(0) = x0, (50b)
where x = (x0, x1, . . . , x2q−1) and x0 = (x0(0), . . . , x2q−1(0)) and matrices A and B can be readily
constructed from the above dynamical equations. This fractional-order initial value problem has the
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closed-form analytical solution [45, Thm. 2.5]
x(t) = Eγ(Atγ)x0 +
∫ t
0
∞∑
k=0
Ak(t− τ)kγ
Γ ((k + 1)γ)
Bu(τ)dτ. (51)
Evidently, the inherent complexity of this closed-form analytical solution — which would require the
evaluation of slowly-converging series — motivates and necessitates the use of numerical methods.
The number of states of system (49) is 2q, therefore, the rational approximation should aim at
a small q. Yet another reason to choose small q is that small values of γ render the system hard to
simulate numerically because they increase the effect of and dependence on the memory.
Adams-Bashforth-Moulton predictor-corrector (ABMPC): Methods of the ABMPC type have been
generalised to solve fractional-order systems. The key idea is to evaluate (rl0 I
γ
f)(t, x(t)) by approxi-
mating f with appropriately selected polynomials. Solutions of Eq. (48) satisfy the following integral
representation
x(t) =
m−1∑
k=0
x0,k
tk
k!
+ (rl0 I
γ
f)(t, x(t)), (52)
where the first term on right hand side will be denoted by Tm−1(t). This is precisely an integral
representation of Eq. (48). The integral on the right hand side of the previous equation can be
approximated, using an uniformly spaced grid tn = nh, by
hγ
γ(γ+1)
∑n+1
j=0 aj,n+1f(tj) for suitable
coefficients aj,n+1 [65]. The numerical approximation of the solution of Eq. (48) is
x(tn+1) = Tm−1(tn+1) + h
γ
Γ (γ+2)f(tn+1, xp(tn+1)) +
n∑
j=1
aj,n+1f(tj , x(tj)). (53a)
The equation above is usually referred to as the corrector formula and xp(tn+1) is given by the
predictor formula
xP (tn+1) = Tm−1(tn) + 1Γ (γ)
n∑
j=0
bj,n+1f(tj , x(tj)). (53b)
Unfortunately, the convergence error of ABMPC when 0 < γ < 1 is O(h1+γ), therefore, a rather
small step size h is required to attain a reasonable approximation error. A modification of the basic
predictor-corrector method with more favourable computational cost is provided in [66] for which the
MATLAB implementation fde12 is available.
Lubich’s method: Fractional linear multi-step methods (FLMM) [63] are a generalisation of lin-
ear multi-step methods (LMM) for ordinary differential equations. The idea is to approximate the
Riemann-Liouville fractional-order integral operator (1) with a discrete convolution, known as a con-
volution quadrature, as
(rl0 I
γ
hf)(t) u h
γ
n∑
j=0
ωn−jf(tj) + hγ
s∑
j=0
wn,jf(tj), (54)
for tj = jh, where (wn,j) and (ωn) are independent of h. Surprisingly, the latter can be constructed
from any linear multistep method for arbitrary fractional order γ [63]. FLMM constructed this way
will inherit the same convergence rate and at least the same stability properties as the original LMM
method [67].
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A MATLAB implementation of Lubich’s method, namely flmm2 [68] which is based on [64] is
available. However, these methods do not perform well for small γ. According to [69], for the case
of amiodarone, it is reported that values of γ smaller than 0.1 give poor results and often do not
converge, while using a crude approximation given by γ = 1/5, flmm2 was shown to outperform fde12
in terms of accuracy and stability at bigger step sizes h.
Numerical inverse Laplace
The inverse Laplace transform of a transfer function F (s) — on the Laplace s-domain — is given by
the complex integral
f(t) = L−1{F}(t) = lim
T→∞
1
2pii
∫ σ+iT
σ−iT
estF (s)ds, (55)
where σ is any real number larger than the real parts of the poles of F . The numerical inverse Laplace
(NILT) approach aims at approximating the above integral numerically. Such numerical methods
apply also to cases where F is not rational as it is the case with fractional-order systems (55).
In the approach of De Hoog et al., the integral which appears in Eq. (55) is cast as a Fourier
transform which can then be approximated by a Fourier series followed by standard numerical inte-
gration (e.g., using the trapezoid rule) [37]. Though quite accurate for a broad class of functions, these
methods are typically very demanding from the computational point of view. An implementation of
the above method is available online [70].
In special cases analytical inversion can be done by means of Mittag-Leffler function [71, 72]. A
somewhat different approach is taken by [73], where authors approximate est, the kernel of the inverse
Laplace transformation, by a function of the form e
st
1+e−2ae2st and choose a appropriately so as to
achieve an accurate inversion.
In general, numerical inversion methods can achieve high precision, but they are not suitable for
control design purposes, especially for optimal control problems. Moreover, there is not one single
method that gives the most accurate inversion for all types of functions. An overview of the most
popular inversion methods used in engineering practice is given in [74].
Drug administration for fractional pharmacokinetics
Approaches for drug administration scheduling can be classified according to the desired objective
into methods where (i) we aim at stabilising the concentration in certain organs or tissues towards
certain desired values (set points) [75] and (ii) the drug concentration needs to remain within certain
bounds which define a therapeutic window [76].
Another level of classification alludes to the mode of administration where we identify the (i)
continuous administration by, for instance, intravenous continuous infusion, (ii) bolus administration,
where the medicine is administered at discrete time instants [76, 77] and (iii) oral administration where
the drug is administered both at discrete times and from a discrete set of dosages (e.g., tablets) [78].
Drug administration is classified according to the way in which decisions are made in regard
to how often, at what rate and/or what amount of drug needs to be administered to the patient.
We can identify (i) open-loop administration policies where the patient follows a prescribed dosing
scheme without adjusting the dosage and (ii) closed-loop administration where the dosage is adjusted
according to the progress of the therapy [75]. The latter is suitable mainly for hospitalised patients
who are under monitoring and where drug concentration measurements are available or the effect of
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the drug can be quantified. Such is the case of controlled anaesthesia [79]. However, applications of
closed-loop policies extend beyond hospitals, such as in the case of glucose control in diabetes [80].
Despite the fact that optimisation-based methods are well-established in numerous scientific disci-
plines along with their demonstrated advantages over other approaches, to date, empirical approaches
remain popular [81–84].
In the following sections we propose decision making approaches for optimal drug administration
using as a benchmark a fractional two-compartment model using, arbitrarily and as a benchmark, the
parameters values of amiodarone. We focus on the methodological framework rather than devising
an administration scheme for a particular compound. We discuss three important topics in optimal
administration of compounds which are governed by fractional pharmacokinetics. Next, we formulate
the drug administration problem as an optimal control problem we prescribe optimal therapeutic
courses to individuals with known pharmacokinetic parameters. Lastly, we design optimal admin-
istration strategies for populations of patients whose pharmacokinetic parameters are unknown or
inexactly known. We present an advanced closed-loop controlled administration methodology based
on model predictive control.
Individualised administration scheduling
In this section we present an optimal drug administration scheme based on the two-compartment
fractional model of Eq. (36) and assuming that the drug is administered into the central compartment
continuously. We will show that the same model and the same approach can be modified to form the
basis for bolus administration.
In order to state the optimal control problem for optimal drug administration we first need to
discretise the two-compartment model (36) with a (small) sampling time tc
t−1c (xk+1 − xk) = Axk + F gl∆1−atc,ν xk +Buk (56)
where xk = [q1(ktc) q2(ktc)]
′ and uk is the administration rate at the discrete time k. The left hand
side of (56) corresponds to the forward Euler approximation of the first-order derivative, and we shall
refer to tc = 10
−2 days as the control sampling time. On the right hand side of (56), gl∆
1−a
tc,ν has
replaced the fractional-order operator c0D
1−α
t . Matrices A,F and B are
A =
[−(k12 + k10) 0
k21,f 0
]
, F =
[
0 k21,f
0 −k21,f
]
, B =
[
1
0
]
. (57)
The discrete-time dynamic equations of the system can now be stated as
xk+1 = xk + tc
(
Axk +
F
t1−ac
ν∑
j=0
c1−aj xk−j +Buk
)
, (58)
where cαj = (−1)j
(
α
j
)
. By augmenting the system with past values as xk = (xk, xk−1, . . . , xk−ν+1) we
can rewrite Eq. (58) as a finite-dimension linear system
xk+1 = Aˆxk + Bˆuk. (59)
Matrices Aˆ and Bˆ are straightforward to derive and are given in [58]. The therapeutic session will
last for Nd = Ntc = 7 days in total, where N is called the prediction horizon. Since it is not realistic
to administer the drug to the patient too frequently, we assume that the patient is to receive their
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treatment every td = 0.5 days. The administration schedule must ensure that the concentration of
drug in all compartments never exceeds the minimum toxic concentration limits while tracking the
prescribed reference value as close as possible. To this aim we formulate the constrained optimal
control problem [85]
min
u0,...,uNd−1
J =
Nd/tc+1∑
k=0
(xref,k − xk)′Q(xref,k − xk) (60a)
subject to the constraints
xk+1 = Aˆxk + Bˆuj , for ktc = jtd (60b)
xk+1 = Aˆxk, otherwise (60c)
0 ≤ xk ≤ 0.5 (60d)
0 ≤ uj ≤ 0.5 (60e)
for k = 0, . . . , N ; j = 0, . . . , Nd − 1.
In the above formulation xref,k is the desired drug concentration at time k and operator
′ denotes
vector transposition. Any deviation from set point is penalised by a weight matrix Q, where here
we chose Q = diag([0 1]). Note that we are tracking only the second state. Our underlying GL
model has a relative history of tcν = 5 days. Optimal drug concentrations are denoted by u
?
k, for
k = 0, . . . , Nd − 1 and they correspond to dosages administered intravenously at times ktd. In the
optimal control formulation we have implicitly assumed that td is an integer multiple of tc, which is
not restrictive since tc can be chosen arbitrarily. In Figure 5 we present the pharmacokinetic profile
of a patient following the prescribed optimal administration course.
Finally, the problem in Eq. (60) is a standard quadratic problem with simple equality and in-
equality constraints that can be solved at low computational complexity. Such problems can be easily
formulated in YALMIP [86] or ForBES [87] for MATLAB or CVXPY [88] for Python.
The optimal control framework offers great flexibility in using arbitrary system dynamics, con-
straints on the administration rate and the drug concentration in the various compartments, and cost
functions which encode the administration objectives.
The quadratic function which we proposed in Eq. (60) is certainly not the only admissible choice.
For instance, other possible choices are
1. J =
∑Nd/tc+1
k=0 (xref,k − xk)′Q(xref,k − xk) + βu2k, where we also penalise the total amount of drug
that is administered throughout the prediction horizon,
2. J =
∑Nd/tc+1
k=0 dist
2(xk, [x, x¯]), where [x, x¯] is the therapeutic window and dist
2(·, [x, x¯]) is the
squared distance function defined as dist2(xk, [x, x¯]) = minzk{‖xk − zk‖2; x ≤ zk ≤ x¯}.
Administration scheduling for populations
In the previous section, we assumed that the pharmacokinetic parameters are known aiming at an
individualised dose regimen. When designing an administration schedule for a population of patients
— without the ability to monitor the distribution of the drug or the progress of the therapy — then J
becomes a function of the pharmacokinetic parameters (in our case k10, k12, k21,f and α). That said,
Fractional Calculus in Pharmacokinetics 21
0 1 2 3 4 5 6 7
0
0.2
0.4
0.6
q
1
(t
)
0 1 2 3 4 5 6 7
time [days]
0
0.2
0.4
0.6
q
2
(t
)
Grünwald-Letnikov
fde12 (ABMPC)
Maximum concentr.
Reference
Fig. 5 Drug administration scheduling via optimal control. The behaviour of the controlled system was simulated
using the ABMPC method (dashed red line). The predicted pharmacokinetic profile using the Gru¨nwald-Letnikov
approximation (solid blue line) and fde12 are indistinguishable. The set-point on q2 (dashed orange line) and the
maximum allowed concentration (black solid lines) are shown in the figure.
J becomes a random quantity which follows an — often unknown or inexactly known — probability
distribution. In order to formulate an optimal control problem we now need to extract a characteristic
value out of the random quantity J . There are two popular ways to do so leading to different problem
statements.
First, we may consider the maximum value of J , max J , over all possible values of k10, k12, k21,f
and α. This leads to robust or minimax problem formulations which consist in solving [85]
min
u0,...,uNd−1
max
k10,k12,k21,f ,α
J(u0, . . . , uNd−1, k10, k12, k21,f , α), (61)
subject to the system dynamics and constraints. In Eq. (61), the maximum is taken with respect to the
worst-case values of k10, k12, k21,f and α, that is, their minimum and maximum values. Apparently,
the minimax approach does not make use of any probabilistic or statistical information which is
typically available for the model parameters. As a result, it is likely to be overly conservative and lead
to poor performance.
On the other hand, in the stochastic approach we minimise the [89] expected cost EJ
min
u0,...,uNd−1
Ek10,k12,k21,f ,α J(u0, . . . , uNd−1, k10, k12, k21,f , α), (62)
subject to the system dynamics and constraints. Open-loop stochastic optimal control methodologies
have been proposed for the optimal design of regimens under uncertainty for classical integer-order
pharmacokinetics [90–92], yet, to the best of our knowledge, no studies have been conducted for the
effectiveness of stochastic optimal control for fractional pharmacodynamics.
The expectation in Eq. (62) can be evaluated empirically given a data-set of estimated pharma-
cokinetic parameters (k
(i)
10 , k
(i)
12 , k
(i)
21,f , α
(i))Li=1 by minimising the sample average of J , that is
min
u0,...,uNd−1
1
L
L∑
i=1
J(u0, . . . , uNd−1, k
(i)
10 , k
(i)
12 , k
(i)
21,f , α
(i)). (63)
22 Pantelis Sopasakis et al.
Fig. 6 Drug administration to a population of 100 (randomly generated) individuals by stochastic optimal control.
The yellow thin lines correspond to the predicted individual responses to the administration and the black lines
represent the average response.
The effect of L on the accuracy of the derived optimal decisions is addressed in [93] where probabilistic
bounds are provided. Simulation results with the stochastic optimal control methodology on a pop-
ulation of 100 patients using L = 20 are shown in Figure 6. Note that in both the minimax and the
stochastic approach, a common therapeutic course u0, . . . , uNd−1 is sought for the whole population
of patients.
In stochastic optimal control it is customary to adapt the state constraints in a probabilistic
context requiring that they be satisfied with certain probability, that is
P[xk ≤ xmax] ≥ 1− β, (64)
where β ∈ [0, 1] is a desired level of confidence. Such constraints are known as chance constraints or
probabilistic constraints. Such problems, unless restrictive assumptions are imposed on the distribution
of xk, lead to nonconvex optimisation problems and solutions can be approximated by Monte Carlo
sampling methods [94, Sec. 5.7.1] or by means of convex relaxations known as ambiguous chance
constraints where (64) are replaced by AV@Rβ [xk] ≤ xmax, where AV@Rβ [xk] is the average value-
at-risk of xk at level β [94, Sec. 6.3.4].
The minimax and the expectation operator are the two “extreme” choices with the former relating
to complete lack of probabilistic information and the latter coming with the assumption of exact
knowledge of the underlying distribution of pharmacokinetic parameters. Other operators can be
chosen to account for imperfect knowledge of that distribution, therefore, bridging the gap between
minimax and stochastic optimal control. Suitable operators for optimal control purposes are the
coherent risk measures which give rise to risk-averse optimal control which is the state of the art in
optimsation under uncertainty [95].
Model Predictive Control
Model predictive control fuses an optimal control open-loop decision making process with closed-loop
control when feedback is available. Following its notable success and wide adoption in the industry,
MPC has been proposed for several cases of drug administration for drugs that follow integer-order
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kinetics such as erythropoietin [96], lithium ions [76], propofol for anaesthesia [97] and, most predom-
inantly, insulin administration to diabetic patients [98–101].
In MPC, at every time instant, we solve an optimal control problem which produces a plan of
future drug dosages over a finite prediction horizon by minimising a performance index J . The future
distribution of the drug in the organism is predicted with a dynamical model such as the ones based on
the Gru¨nwald-Letnikov discretisation presented in the previous sections. Out of the planned sequence
of dosages, the first one is actually administered to the patient. At the next time instant, the drug
concentration is measured and the same procedure is repeated in a fashion known as receding horizon
control [102].
A fractional variant of the classical PID controller, namely a PIλDµ fractional-order controller,
has been proposed in [103] for the controlled administration. However, the comparative advantage of
MPC is that it can inherently account for administration rate, drug amount and drug concentration
constraints which are of capital importance. In [46, 58], the truncated Gru¨nwald-Letnikov approxi-
mation serves as the basis to formulate MPC formulations with guaranteed asymptotic stability and
satisfaction of the constraints at all time instants. We also single out impulsive MPC, which was
proposed in [76], which is particularly well-suited for applications of bolus administration where the
patient is injected the medication (e.g., intravenously), thus abruptly increasing the drug concentra-
tion. In such cases, it is not possible to achieve equilibrium, but instead the objective becomes to keep
the concentration within certain therapeutic limits. Model predictive control can further be combined
with stochastic [104, 105] and risk-averse [95] optimal control aiming at a highly robust administration
that is resilient to the inexact knowledge of the pharmacokinetic parameters of the patient as well
as potential time varying phenomena (e.g., change in the PK/PD parameter values due to illness,
drug-drug interactions and alternations due to other external influences).
Furthermore, in feedback control scenarios, state information is often partially available. For ex-
ample, when a multi-compartment model is used, concentration measurement from only a single
compartment is available. As an example, in the case of multi-compartment physiologically based
models, we would normally only have information from the blood compartment. In such cases, a state
observer can be used to produce estimates of concentrations or amounts of drug in compartments
where we do not have access. A state observer is a dynamical system which, using observations of
(i) those concentrations that can be measures and (ii) amount or rate of administered drug at ev-
ery time instant, produces estimates qˆi of those amounts/concentrations of drug to which we do not
have access. State observers are designed so that qˆi(t) − qi(t) → 0 as t → ∞, that is, although at
the beginning (at t = 0) we only have an estimate qˆi(0) of qi(0), we shall eventually obtain better
results which converge to the actual concentrations. State observers, such as the Kalman filter, have
been successfully employed in the administration of compounds following integer-order dynamics [75]
including applications of artificial pancreas [106, 107].
Observers are, furthermore, employed to filter out measurement errors and modelling errors. When
the system model is inexact, the system dynamics in Eq. (59) becomes
xk+1 = Aˆxk + Bˆuk + dk, (65)
where dk serves as a model mismatch term. We may then assume that dk follows itself some dynamics
often as trivial as dk+1 = dk. We may then formulate the following linear dynamical system with state
(xk, dk) [
xk+1
dk+1
]
=
[
Aˆ I
0 I
] [
xk
dk
]
+
[
Bˆ
0
]
uk, (66)
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and build a state observer for (xk, dk) jointly. The estimates (xˆk, dˆk) are then fed to the MPC. This
leads to an MPC formulation known as offset-free MPC [75] that can control systems with biased
estimates of the pharmacokinetic parameters.
Model predictive control is a highly appealing approach because it can account for imperfect
knowledge of the pharmacokinetic parameters of the patient, measurement noise, partial availability
of measurements and constraints while it decides the amount of administered drug by optimising
a cost function thus leading to unparalleled performance. Moreover, the tuning of MPC is more
straightforward compared to other control approaches such as PID or fractional PID. In MPC the
main tuning knob is the cost function J of the involved optimal control problem which reflects and
encodes exactly the control objectives.
Conclusions
Fractional kinetics offers an elegant description of anomalous kinetics, i.e., non-exponential terminal
phases, the presence of which has been acknowledged in pharmaceutical literature extensively. The
approach offers simplicity and a valid scientific basis, since it has been applied in problems of diffusion
in physics and biology. It introduces the Mittag-Leffler function which describes power law behaved
data well, in all time scales, unlike the empirical power-laws which describe the data only for large
times. Despite the mathematical difficulties, fractional pharmacokinetics offer undoubtedly a powerful
and indispensable approach for the toolbox of the pharmaceutical scientist.
Solutions of fractional-order systems involve Mittag-Leffler-type functions, or other special func-
tions whose numerical evaluation is nontrivial. Several approximation techniques have been proposed
as we outlined above for fractional systems with different levels of accuracy, parsimony and suitability
for optimal administration scheduling or control. In particular, those based on discrete time-domain
approximations of the system dynamics with bounded approximation error, such as the truncated
Gru¨nwald-Letnikov approximation, are most suitable for optimal control applications. There nowa-
days exist software that implement most of the algorithms that are available in the literature and
facilitate their practical use. Further research effort needs to be dedicated in deriving error bounds
in the time domain for available approximation methods that will allow their adoption in optimal
control formulations.
The optimal control framework is suitable for the design of administration courses both to indi-
viduals as well as to populations where the intra-patient variability of pharmacokinetic parameters
needs to be taken into account. In fact, stochastic optimal control offers a data-driven decision making
solution that enables us to go from sample data to administration schemes for populations. Optimal
control offers great flexibility in formulating optimal drug dosing problems and different problem
structures arise naturally for different modes of administration (continuous, bolus intravenous, oral
and more). At the same time, further research is necessary to make realistic assumptions and translate
them into meaningful optimisation problems.
MPC methodologies are becoming popular for controlled drug administration. Yet, their potential
for fractional-order pharmacokinetics and their related properties, especially in regard to stochastic
systems and the characterisation of invariant sets, needs to be investigated.
Overall, at the intersection of fractional systems theory, pharmacokinetics, numerical analysis,
optimal control and model predictive control, spring numerous research questions which are addressed
in the context of mathematical pharmacology.
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